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The role of the mitochondrial protein receptor Tom22p in the interaction of pro-apoptotic protein
Bax with yeast mitochondria was investigated. Co-immunoprecipitation assays showed that human
Bax interacted with different TOM subunits, including Tom22p. Expression of the cytosolic receptor
domain of human Tom22 increased Bax mitochondrial localization, but decreased the proportion of
active Bax. BN–PAGE showed that the cytosolic domain of Tom22 interfered with the oligomeriza-
tion of Bax. These data suggest that the interaction with the cytosolic domain of Tom22 helps Bax
to acquire a conformation able to interact with the outer mitochondrial membrane.
Structured summary of protein interactions:
BAX and BAX physically interact with TOM22 by anti bait coimmunoprecipitation (View interaction)
BAX physically interacts with TOM70 by anti bait coimmunoprecipitation (View interaction)
BAX physically interacts with TOM22, TOM70 and TOM40 by anti bait coimmunoprecipitation (View
interaction)
BAX physically interacts with TOM22 by anti bait coimmunoprecipitation (View interaction)
BAX and BAX bind by blue native page (View interaction)
BAX physically interacts with TOM40 by anti bait coimmunoprecipitation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction The involvement of outer mitochondrial membrane proteins inApoptosis, themain formof programmed cell death, is controlled
by proteins of the Bcl-2 family [1]. Among them, the pro-apoptotic
protein Bax promotes the permeabilization of the mitochondrial
outer membrane to apoptogenic factors such as cytochrome c,
smac/diablo, or apoptosis inducing factor [2]. The translocation of
Bax from the cytosol to mitochondria is a crucial early step of apop-
tosis, and is associated to conformational changes from a soluble
conformation to a membrane-inserted conformation, by exposing
more hydrophobic domains of the protein [3,4].chemical Societies. Published by E
ng; BH, Bcl-2 homology; BN/
rylamide gel electrophoresis;
uter membrane
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no, Department of Chemistry,the different steps leading to Bax translocation, insertion and activa-
tion is still debated [5]. Antibodies directed against Tom22 prevent
Bax membrane insertion on isolated mammalian mitochondria
and the down-regulation of Tom22 inhibits Bax-dependent apopto-
sis in human glioblastoma cells [6,7]. These effects are selective for
Tom22 since the modulation of Tom20 does not have any effect on
Bax translocation [6]. When expressed in yeast, human Bax is less
efﬁciently localized to mitochondria in a strain containing less
Tom22p [6] and the consequences on yeast growth are attenuated
[8]. These data were challenged by another report [9] that used re-
combinant N-terminal hexahistidine-tagged Bax added to isolated
mitochondria. Since movements of the N-terminal end of Bax are
crucial for its conformational changes [10,11], this tagged Baxmight
not accurately recapitulate the steps underlying Bax translocation.
Furthermore, as shown in the original paper describing the produc-
tion of this recombinant protein [12], it is contaminated by a trun-
cated form of Bax called p18, that promotes the membrane
addressing of full-length Bax [13] and does not therefore reﬂect
the behavior of full-length Bax alone. Two other reports thatlsevier B.V. All rights reserved.
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the utilization of a mutant carrying a mutation of S184 [14,15], but
the deletion of S184 in helixa9 had been shown to change this helix
into a constitutive sequence of insertion into the outer mitochon-
drial membrane [16] and the resulting Bax mutant did not require
anymore the presence of Tom22p for mitochondrial translocation
[6].
In the present study, we report that, like in mammalian cells,
human Bax and yeast Tom22 physically interact. Furthermore,
the modulation of this interaction by a competing peptide corre-
sponding to the cytosolic receptor domain of human Tom22, mod-
ulated not only the translocation, but also the conformation and
the oligomeric status of Bax in the outer mitochondrial membrane.
2. Methods
2.1. Yeast strains and plasmids
The haploid wild-type strain W303-1A (mata, ade1, his3, leu2,
trp1, ura3) was transformed with the pYES3 plasmid carrying a
reprogrammed version of human Bax cDNA (optimized for high
expression in yeast) under the control of the GAL1/10 promoter.
The human Bax protein produced by this construction is full-length
(192 residues) and untagged. Mutations of Proline residues at posi-
tions 8, 13, and 168 have been described previously [17]. The
pYES2 plasmid carrying a truncated version of human Tom22 (res-
idues 1-82; hTom22(1-82)) under the control of the GAL1/10 pro-
moter has been constructed by amplifying the corresponding
fragment from a human cDNA library. Cells were grown in Yeast
Nitrogen Base medium supplemented with DL-Lactate as a carbon
source to obtain fully differentiated mitochondria. Bax-expression
and hTom22(1-82) expression was induced by adding 0.5% galact-
ose to the cultures.
2.2. Bax and cytochrome c contents of yeast mitochondria
Mitochondria were isolated from cells grown overnight (14 h).
Proteins from isolated mitochondria (50 lg proteins) were precip-
itated with 0.3 M TCA, washed with acetone, and solubilized in 2%
SDS before to be separated on SDS–PAGE, blotted and analyzed
with an anti-Bax antibody (N20, Santa-Cruz). Cytochromes content
was measured by redox spectrophotometry. Brieﬂy, mitochondria
(3 mg proteins) were suspended in the two cuvettes of a double-
beam spectrophotometer (Varian Cary 4000). The reference and
sample cuvettes were oxidized and reduced with potassium ferri-
cyanide and sodium dithionite, respectively. Difference spectra
were acquired between 500 and 650 nm and cytochromes c+c1,
cytochrome b and cytochromes a+a3 were quantiﬁed from the
O.D. differences between 550 minus 540, 561 minus 575, and 603
minus 630 nm, respectively.
2.3. Co-immunoprecipitation assays
Yeast cells were grown in 20 ml cultures and washed in 10 mM
tris/maleate buffer (pH 6.8) containing 0.6 M mannitol, 2 mM
EGTA, antiproteases (Complete™, Roche) and antiphosphatases
(1 mM sodium vanadate, 10 mM sodium ﬂuoride, and PhosStop™,
Roche). Cells were resuspended in the same buffer and were bro-
ken by vortexing with glass beads for 3 min in a FastPrep (MP Bio-
chemicals). Unbroken cells and nuclei were eliminated by a 10-min
900g centrifugation. Supernatants were added with 1/9 volume
of 10 IP buffer (Sigma) and gently shaken at 4 C for 30 min.
Immunoprecipitations were done overnight with 2 lg of mouse
monoclonal anti-Bax antibodies (2D2 or 6A7, Sigma). 50 ll Protein
G-agarose beads (Sigma) were added and incubated for 4 h. Afterextensive washing with 5  0.5 ml of IP buffer 1 and 2  0.5 ml
of IP buffer 0.1, proteins were eluted with 30–50 ll 0.2 M glycine,
pH 2.8. Protein samples were solubilized in Laemmli buffer with-
out b-mercaptoethanol.
Western blottings were done with the following antibodies: Bax
(rabbit polyclonal N20, Santa-Cruz, 1/5000), yeast Tom22 (custom
rabbit polyclonal, Millegen, 1/2000), yeast Tom20, Tom40 and
Tom70 (rabbit polyclonal, gifts from Dr Carla Koehler, 1/5000),
yeast Porin (mouse monoclonal, Invitrogen, 1/20000), yeast phos-
phoglycerate kinase (mouse monoclonal, Invitrogen, 1/10000),
yeast cytochrome c oxidase subunit II (mouse monoclonal, Invitro-
gen, 1/10000). Immunoblots were revealed with Western Light-
ning plus (Perkin–Elmer) and quantiﬁed with a G-Box imaging
system (Syngene).
2.4. Mammalian cells
Cultures of FL5.12 cells, induction of apoptosis and co-immuno-
precipitation assays were done as described in [18].
2.5. BN–PAGE analyzes
Mitochondria were suspended at 1 mg/ml in 50 mM imidazole/
HCl buffer (pH 7.2) containing 50 mM NaCl and 5 mM e-aminoca-
proic acid. Digitonin-solubilization was done for 20 min on ice at
detergent/protein ratio of 0.3 (w/w). Non-solubilized material
was removed by centrifugation at 21000g for 20 min. The super-
natant was supplemented with Coomassie dye solution (5% Serva
Blue G in 750 mM e-aminocaproic acid) at a dye/protein ratio of
0.2 (w/w) and separated on a linear gradient (5–14%) polyacryl-
amide slab gel. Molecular weight markers were treated in a similar
manner before loading on the gel. Second dimension electrophore-
sis was done on each individual lane from the BN–PAGE. Lanes
were excised and layered on the top of a 12.5% SDS–PAGE for the
second dimension. Western-Blotting were done with polyclonal
anti-Bax (N20, Santa-Cruz, 1/1000).
Electrophysiological studies were done on proteoliposomes
containing the outer mitochondrial isolated from a Dpor1 strain
expressing or not C-terminal c-myc tagged human Bax as described
in [19].
3. Results
3.1. Mitochondrial human Bax physically interacts with both yeast and
mammalian Tom22p
Although the sequence conservation between the products of
yeast and human TOM22 is weak (Fig. 1A), human Tom22 is able to
complement the absence of yeast Tom22p suggesting that the
interaction between Tom22 and mitochondria-addressed proteins
involves a general conformation recognition process [20]. When
expressed in yeast, wild-type human Bax (without any tag) largely
resides in the cytosol, like in non-apoptotic mammalian cells, and
the translocation of Bax to mitochondria is stimulated by introduc-
ing point mutations at critical positions that favor the activating
conformational change [17]. One of these constitutively mitochon-
drial and active mutants both in yeast and human cells is BaxP168A
[17,21]. This mutation increases the mobility of the C-terminal
hydrophobica9 helix, allowing itsmovement away from the hydro-
phobic groove formed by the BH domains.
We found yeast Tom22p, Tom40p and Tom70p in BaxP168A-
immunoprecipitates (Fig. 1B), suggesting that active Bax was asso-
ciated to the TOM complex. Additional evidence for the interaction
between Bax and yeast Tom22 was obtained by electrophysiology
of the PSC, that reﬂects the activity of TOM: the cation selectivity
Fig. 1. Interaction between human Bax and TOM components. (A) Sequence alignment of human and yeast Tom22. Dark grey: identical residues; light grey: similar residues.
(B) Co-immunoprecipitation of yeast mitochondrial proteins with the constitutively active BaxP168A mutant was done as indicated in the methods section. The intense band
at the top of the Por1p lane corresponds to the size of the mouse IgG. A faint band can be detected at 31 kDa, the expected size of Por1p. Bax is detected at 21 kDa with some
minor bands above, Tom22 at 18 kDa, and Tom70 and Tom40 at 70 and 40 kDa, respectively. (C) Co-immunoprecipitation of Tom22 but not Tom20 by Bax in apoptotic FL5.12
cells.
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presence of Bax, further supporting the existence of a lingering
interaction between Bax and TOM. In parallel, immunoprecipita-
tion of wild-type Bax in pro-lymphocytic FL5.12 cells submitted
to apoptosis by IL-3 removal revealed that Bax co-immunoprecip-
itated with Tom22 but not with Tom20 (Fig. 1C). This result was in
accordance with previous reports in glioblastoma cells, where
Tom22p but not Tom20p was required for Bax translocation [6].
3.2. The cytosolic part of human Tom22 interferes with Bax
conformational changes
Since the full inactivation of TOM22 gene dramatically decreases
yeast growth, it was not possible to use a null strain to investigate
further the role of Tom22p on Bax interaction with mitochondria.
Instead, we set up a paradigm based upon the competition of Baxbinding to Tom22p by a peptide corresponding to the cytosolic part
of human Tom22 (82 ﬁrst residues [22,23]) and lacking the trans-
membrane domain of the protein. We reasoned that the interaction
of Bax with this peptide would prevent Bax interaction with
Tom22p and thus impair Bax interaction with mitochondria.
The peptide was co-expressed in yeast with three Bax variants:
Bax a, the wild-type protein that is inactive and poorly localized to
mitochondria, the double mutant BaxP8G/P13G, that is more active
both on mammalian and yeast mitochondria because of the higher
ﬂexibility of ART [11,17], and the single mutant BaxP168A that is
strongly active both on mammalian and yeast mitochondria
because of the higher ﬂexibility of the turn between a8 and a9
helices [17,21].
Unexpectedly, the co-expressionof hTom22(1-82)with the three
Bax variants increased their mitochondrial localization (Fig. 2A and
B). We further determine if Bax was active by measuring the
Fig. 2. Co-expression of hTom22(1-82) increases Bax mitochondrial localization. Cells were co-transformed with the pYES3 vector carrying wild-type or mutants of human
Bax and the pYES2 vector carrying or not a gene encoding hTom22(1-82). Mitochondria were isolated from cells as indicated in the methods section. (A) Mitochondrial Bax
amount was estimated by western-blotting, with subunit II of cytochrome c oxidase (cox2) and Phosphoglycerate kinase (pgk1) serving as controls for mitochondrial and
cytosolic proteins, respectively. (B) Quantiﬁcation of western-blots. Results are average of 3 or 4 independent experiments ± S.E.M. Note that the mitochondrial localization of
Bax wild-type may vary from experiment to experiment: in this series of experiments, it is relatively high (as compared to, for instance, data from [17]. (C) The amounts of
cytochromes c and b in isolated mitochondria were measured by redox difference spectrophotometry. (D) Quantiﬁcation of cyt.c/cyt.b ratios. Values are average (±S.E.M.) of 4
independent experiments.
Fig. 3. hTom22(1-82) modulates Bax conformation. (A) Cells were co-expressing wild-type Bax or the mutant P168A and hTom22(1-82). Bax was immunoprecipitated from
cell extracts with 2D2 or 6A7 monoclonal antibodies. Western-blots were revealed with the polyclonal N20 antibody. (B) Quantiﬁcation of western-blots. Ratios of the signal
obtained with 6A7 and 2D2 were calculated and the values obtained in the absence of Tom22(1-82) peptide were ﬁxed at 1. Values are averages of three independent
experiments (±S.E.M.). (C) Cell extracts from cells co-expressing BaxP168A and Tom22(1-82) were immunoprecipitated with anti-Bax antibody (2D2) and western-blots were
revealed with antibodies against TOM subunits. (D) Quantiﬁcation of (C). Values are average ± S.E.M. of 3 independent experiments.
T.T. Renault et al. / FEBS Letters 586 (2012) 116–121 119
120 T.T. Renault et al. / FEBS Letters 586 (2012) 116–121remaining cytochrome c content of isolated mitochondria (Fig. 2C):
cytochrome c release was not stimulated by the presence of
hTom22(1-82) (Fig. 2D), showing that the additional amount of
mitochondrial Bax was not active. This suggested that, in the pres-
ence of hTom22(1-82), inactive wild-type Bax could be addressed
to mitochondria. This hypothesis was further tested by comparing
immunoprecipitates obtained with two different anti-Bax antibod-
ies: 2D2 that recognizes all Bax conformations, and 6A7 that only
recognizes the active conformation [24,25]. Wild-type Bax and Bax-
P168Awere tested (Fig. 3A). hTom22(1-82) did not change the bind-
ing of either 2D2 or 6A7 antibodies to the constitutively active
mutant BaxP168A. On the opposite, it decreased the recognition of
wild-type Bax by 6A7 (Fig. 3A and B), suggesting that it favored
the inactive conformation of Bax. The fact that hTom22(1-82) did
not change the interaction between Bax and Tom22p, Tom40p or
Tom70p (Fig. 3C and D), further supported the view that the effect
of the hTom22(1-82) did not result from a simple competing effect
with the TOM complex but had a direct effect on Bax conformation.
3.3. The cytosolic part of human Tom22 interferes with Bax
oligomerization
These data suggested that hTom22(1-82) forced Bax to acquire
a mitochondria-localized but inactive conformation. Since the acti-
vation of Bax depends on its capacity to oligomerize, we investi-
gated the effect of hTom22(1-82) on Bax oligomeric status by
BN–PAGE. The mutant BaxP8G/P13G was used for this experiment
since it is only partially active and both stimulatory and inhibitory
changes could be potentially detected.
In the ﬁrst dimension (Fig. 4, horizontal direction) BaxP8G/P13G
was observed as a range of oligomers between 200 and 350 kDa. In
the presence of hTom22(1-82), this proﬁle disappeared and was re-
placed by a streak below 200 kDa, showing that oligomers formed
in the presence of the peptide had a lower size. A second dimen-
sion was run by layering the ﬁrst-dimension lane on top of a
SDS–PAGE. These conditions preserve organized protein com-
plexes, such as the oligomers of ATP synthase subunit 9. After this
second dimension (Fig. 4, vertical direction), BaxP8G/P13G ex-
pressed alone was mainly found at 21 kDa, the size of Bax mono-
mer, with only a minor band at 43 kDa, the size of Bax dimers. In
the presence of hTom22(1-82), monomeric Bax could not be de-
tected, and Bax was fully dimeric. This suggests that hTom22(1-
82) stimulated the formation of a dimer of Bax that could not fur-
ther oligomerize.Fig. 4. The peptide corresponding to the cytosolic part of Tom22 favors the dimerizat
expressing the Bax mutant P8G/P13G and Tom22(1-82) were analyzed by two-dimensio
revealed with anti-Bax antibody (N20). The experiment shown is representative of 4 ind4. Discussion
Data reported in this paper further support the hypothesis that
the mitochondrial translocation of Bax may be modulated by the
cytosolic domain of the mitochondrial receptor Tom22. It had been
previously reported that puriﬁed Bax and mammalian Tom22
physically interacted, and that down-regulating Tom22 impaired
apoptosis in human glioblastoma cells [6,7]. A role for Tom22 in
Bax effects has also been reported in Drosophila [26], where the
partial loss of function of Tom22 or Tom70 attenuated the pheno-
types linked to heterologous human Bax-expression in ﬂies. Also,
the down-regulation of yeast Tom22 decreased the localization of
human Bax in yeast mitochondria [6].
In the present work, we show that this functional interaction
between human Bax and yeast Tom22p actually resulted from a
physical interaction, since we found that Bax co-immunoprecipi-
tated with Tom22p, Tom40p and Tom70p (Fig. 1B). However, the
two later might not interact directly with Bax, as already suggested
for Tom40p [8], but indirectly through their association with
Tom22p. Also, Bax slightly modulates the electrophysiological
properties of PSC, the channel associated to yeast TOM. Like previ-
ously observed in glioblastoma cells [6], Bax and Tom22 also phys-
ically interacted in apoptotic pro-lymphocytic cells (Fig. 1C),
showing that this interaction was not limited to one mammalian
cell type.
To further investigate the role of this physical interaction be-
tween Bax and Tom22p, Bax mutants were co-expressed with
the cytosolic receptor domain of human Tom22. We observed an
increase of mitochondrial localization of all three Bax variants
(Fig. 2A and B) that was not associated to an increase of their activ-
ity (Fig. 2D). Furthermore, the peptide decreased the proportion of
6A7-positive wild-type Bax (Fig. 3A and B). This showed that the
additional mitochondrial Bax remained under an inactive confor-
mation unable to oligomerize and to form a channel. BN–PAGE
analyses indeed supported the hypothesis that the hTom22 recep-
tor peptide forced Bax to acquire a dimeric conformation that
could not further oligomerize up to the same size as control Bax
(Fig. 4) and may represent a ‘‘dead end’’ in the process.
This effect of hTom22 receptor peptide may provide a new in-
sight on the role of Tom22 in the process leading to Bax transloca-
tion and activation. Recent data showed that Bax displays two
domains of interactions [27,28]. On this basis, Bax would be able
to form stable symmetric dimers or unstable asymmetric dimers,
the later being further assembled into high-size oligomers [4].ion and prevents the oligomerization of Bax. Mitochondria isolated from cells co-
nal BN–PAGE/SDS–PAGE, as described in the experimental procedures section, and
ependent experiments.
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tion step of Bax towards the outer mitochondrial membrane, but
would not be sufﬁcient to promote the full activation of the pro-
tein. Hence, the hTom22 receptor peptide may ‘‘force’’ the translo-
cation step even though Bax is not under the adequate
conformation to oligomerize, leading to the formation of a mem-
brane-localized but inactive dimer.
These observations made in the yeast model system that allows
to reproduce the translocation and activation steps of Bax, will now
be evaluated in mammalian cell lines to evaluate the effects on
apoptosis. Like in yeast, it is difﬁcult to down-regulate mammalian
Tom22 without compromising cell survival. The expression of
hTom22(1-82) will be a valuable tool to investigate further the role
of Tom22 in apoptosis. Another point of interest is the respective
role of TOM receptors Tom20, Tom22 and Tom70. It has been sug-
gested that Tom20 could serve as a receptor for Bcl-2 [29] but
down regulation of Tom20 did not alter Bax-dependent apoptosis
in glioblastoma cells [6]: this suggests that Tom20 and Tom22
might have distinct functions in regulating the mitochondrial
localization of Bcl-2 family members. However, data suggest that
both receptors are involved in the same mitochondrial import
pathway [30]. This may indicate that distinct domains of both
Tom20 and Tom22 are involved in their import function and in
their capacity to modulate Bcl-2/Bax translocation. The expression
of shorter domains of the cytosolic part of Tom22 might help to
clarify this point.
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